Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
about
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapyIsoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersGenome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE studyTuberculosis drug development: ensuring people living with HIV are not left behind.Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.Individualization of antiretroviral therapy.Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.EFV/FTC/TDF-associated hepatotoxicity: a case report and review.Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisMultiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Pharmacogenetic considerations in the treatment of HIV.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis.Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without TuberculosisLong-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
P2860
Q28539806-AD3F9FA0-07F7-4E0B-BE3A-22673886E4EEQ33798516-A629DBBA-A0BD-41CB-B840-AF2CD328BE12Q34455442-582337AF-788A-46C5-B416-E518918F98D2Q34756398-6FA11766-6561-4777-9A1F-4C817BF67A10Q35065867-C839B6C1-320C-4DA9-AFAF-351C53CE43AEQ35288691-A3AF65C5-109C-4EC0-9819-13DCB57C4442Q35974648-3DAEE0AD-BEA8-4D6F-995B-4F8A832FD92EQ35991204-CC6172EE-42D9-43FD-AAB8-A02888C58965Q36171561-FDA4F8C7-293A-42FF-A795-80F1E27B7668Q36441423-8517AB9E-A7BF-465A-BDD1-5CC6C2239D2CQ37036991-70016588-1218-4171-9974-EFEEEC49E44CQ37139458-41DC3ABA-ECAC-4B07-9D55-99CF37639736Q37153012-901AACB6-E84F-4146-8634-C440C7DC5B17Q37429325-81C0442D-37FB-4260-A6D6-54BF2E090B3AQ37466856-93B99C7B-05C0-47FB-BFAE-06406647E707Q37617319-EBDA25E8-F050-4AAB-B643-2FE659CF3616Q37626582-720B88ED-954F-4E69-9DA8-67A59AF8DD61Q38107500-E213946B-EAA6-4860-BE9B-434A22E9E84FQ38207924-8DB834E8-546B-4B38-BEA7-FD02DCB63C5DQ38782609-2D792FC3-9C54-41B8-BC68-2265A654ECDFQ38861140-3B4AFD37-AAB8-4CAB-A8F7-03B13E0FE5A4Q39039468-03F17FE3-4E30-4880-9E5A-4E51D6800EFDQ39503882-F686ECB6-97E8-43A7-BBC6-00985FA743B7Q40694902-A49D9FEA-037F-4C6D-94ED-B498B0F33D1CQ40851546-AB4378F3-3B69-450F-8D0B-339A75733275Q44132038-BC501721-A438-4D65-B85D-42362A513692Q56829837-B6CA86AF-1188-45CF-B515-61947887F179Q58612379-DDDFCCAB-D891-4758-9BE5-8A2455318D93
P2860
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Paradoxically elevated efavire ...... ining antituberculous therapy.
@en
Paradoxically elevated efavire ...... ining antituberculous therapy.
@nl
type
label
Paradoxically elevated efavire ...... ining antituberculous therapy.
@en
Paradoxically elevated efavire ...... ining antituberculous therapy.
@nl
prefLabel
Paradoxically elevated efavire ...... ining antituberculous therapy.
@en
Paradoxically elevated efavire ...... ining antituberculous therapy.
@nl
P2093
P1433
P1476
Paradoxically elevated efavire ...... ining antituberculous therapy.
@en
P2093
Awewura Kwara
Kwamena W Sagoe
Margaret Lartey
Michael H Court
P304
P356
10.1097/QAD.0B013E3283427E05
P407
P577
2011-01-01T00:00:00Z